Printer Friendly

LECTEC AND UNIVERSITY OF MINNESOTA PURSUE SAFER ALTERNATIVE TO NICOTINE FOR SMOKING CESSATION PATCHES

 LECTEC AND UNIVERSITY OF MINNESOTA PURSUE SAFER ALTERNATIVE TO
 NICOTINE FOR SMOKING CESSATION PATCHES
 MINNETONKA, Minn., June 17 /PRNewswire/ -- Based on concerns that a nicotine patch may not be the most effective or safe product for smoking cessation, LecTec (NASDAQ: LECT) researchers sought a safer medication. An agreement was jointly announced between the University of Minnesota and LecTec in January 1992 for a nicotine-free smoking cessation product. Under the terms of the agreement, a transdermal and an oral dosage form of a non-nicotine active ingredient for smoking cessation are being developed.
 Human and animal studies have demonstrated the non-addictive properties of the nicotine-free active. Studies also indicate that the future transdermal product will be less toxic and, thus, safer to use than existing nicotine-containing products. A patent has been filed and is pending.
 LecTec has been in contact with several prominent partners and expects soon to finalize an alliance to assure expeditious distribution of the future product. The company has two FDA registered pharmaceutical manufacturing facilities and is positioned to meet market volume projections.
 Nicotine is known to be toxic and can induce symptoms of nausea, vomiting, headache, dizziness and neurological stimulation which causes palpitation of the heart, increased blood pressure, accelerated breathing, perspiration and salivation. The dangers of smoking are well known.
 LecTec is one of the pioneers in the research of monolithic transdermal delivery systems for various drugs. Among the first projects pursued by the company was a transdermal dosage form for nicotine. The product was planned to be used as a smoking cessation treatment. Prototype products were submitted to an internationally recognized pharmaceutical company and a patent position established.
 The LecTec nicotine delivery system was promising and demonstrated unique advantages over other transdermal technologies. However, concern arose among the company's researchers in 1987 regarding potential shortcomings and dangers of a nicotine patch for smoking cessation.
 Research and results of smoking cessation therapies recently presented by the University of Minnesota Medical School highlighted limitations of current nicotine-containing smoking cessation products. (Smoking Cessation Update and Intervention Strategies, May 29, 1992.) Various medical clinics, such as Park Nicollet of Minneapolis and the world famous Mayo Clinic, have established programs using behavioral therapies to enhance current smoking cessation products. ("Crushing Out Smoking Addiction," Robert D. Christensen, M.D., General Surgery, Park- Nicollet Clinic; Minnesota Medicine, Vol. 73, No. 4, March 1990, p. 44.) Noted Dr. Richard D. Hunt, director of the Nicotine Dependence Center at the Mayo Clinic, Rochester, Minn.: "By itself, the patch isn't magic."
 In the United States alone, there are an estimated 50 million smokers. The potential market in the United States for smoking cessation products is projected to exceed $1 billion. The market is currently faced with demand far exceeding supply and little product differentiation among the transdermals, all of which contain nicotine as the active ingredient.
 LecTec Corporation is a medical company that develops, manufactures and markets a variety of skin-related products. In addition to transdermal drug delivery products, LecTec also produces cardiac diagnostic and monitoring electrodes, medical tapes and conductive- adhesive hydrogel polymers. LecTec is headquartered in Minnetonka, with an additional facility in Edina, Minn. The company is publicly traded on NASDAQ under the symbol LECT.
 -0- 6/17/92
 /CONTACT: Jan Jachimowicz of LecTec Corporation, 612-933-2291/
 (LECT) CO: LecTec Corporation; University of Minnesota ST: Minnesota IN: MTC SU: PDT


DS -- MN005 -- 1007 06/17/92 10:31 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 17, 1992
Words:564
Previous Article:LOMAS FINANCIAL CORPORATION MAKES ANNOUNCEMENT
Next Article:TYLER CABOT MORTGAGE SECURITIES FUND ANNOUNCES PROPOSED MERGER WITH CAPSTEAD MORTGAGE CORPORATION
Topics:


Related Articles
LECTEC BOARD APPROVES ADDED EMPHASIS ON TRANSDERMAL BUSINESS DEVELOPMENT; CITES SIGNIFICANT OPPORTUNITIES
LECTEC REVIEWING POSSIBLE PATENT INFRINGEMENTS OF TRANSDERMAL NICOTINE TECHNOLOGY
PROSTEP NICOTINE TRANSDERMAL SYSTEM RECEIVES APPROVAL
LECTEC BOARD INTENSIFIES FUNDING FOR TRANSDERMAL PATCH DEVELOPMENT; TO TREAT SMOKERS, CANCER PATIENTS, OTHERS
CYGNUS SHIPS ITS NICOTINE PATCH
PARKE-DAVIS LAUNCHES NICOTROL, FIRST NICOTINE PATCH FOR WAKING HOURS USE
ATP ACQUIRES WORLDWIDE RIGHTS TO NEW NICOTINE INHALER TECHNOLOGY
NEW YEAR'S RESOLUTION SURVEY SHOWS HEALTH AS IMPORTANT GOAL FOR 1993
NEW YEAR'S RESOLUTION SURVEY SHOWS HEALTH AS IMPORTANT GOAL FOR 1993; SMOKING CESSATION A PRIORITY FOR SMOKERS AND NON-SMOKERS
CYGNUS 'WAKING HOURS' NICOTINE PATCH SHOWS IMPRESSIVE RESULTS IN A RECENT STUDY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters